276 related articles for article (PubMed ID: 23591780)
1. Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.
Parrott N; Hainzl D; Alberati D; Hofmann C; Robson R; Boutouyrie B; Martin-Facklam M
Clin Pharmacokinet; 2013 Aug; 52(8):673-83. PubMed ID: 23591780
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin.
Parrott N; Hainzl D; Scheubel E; Krimmer S; Boetsch C; Guerini E; Martin-Facklam M
AAPS J; 2014 Sep; 16(5):1077-84. PubMed ID: 24970349
[TBL] [Abstract][Full Text] [Related]
3. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
4. Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.
Feng S; Shi J; Parrott N; Hu P; Weber C; Martin-Facklam M; Saito T; Peck R
Clin Pharmacokinet; 2016 Jul; 55(7):823-832. PubMed ID: 26715215
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
7. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
[TBL] [Abstract][Full Text] [Related]
8. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
9. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers.
Martin-Facklam M; Pizzagalli F; Zhou Y; Ostrowitzki S; Raymont V; Brašić JR; Parkar N; Umbricht D; Dannals RF; Goldwater R; Wong DF
Neuropsychopharmacology; 2013 Feb; 38(3):504-12. PubMed ID: 23132267
[TBL] [Abstract][Full Text] [Related]
10. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
11. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
Hofmann C; Pizzagalli F; Boetsch C; Alberati D; Ereshefsky L; Jhee S; Patat A; Boutouyrie-Dumont B; Martin-Facklam M
Psychopharmacology (Berl); 2016 Jul; 233(13):2429-39. PubMed ID: 27178435
[TBL] [Abstract][Full Text] [Related]
12. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
14. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
16. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy for physiologically based predictions of human pharmacokinetics.
Jones HM; Parrott N; Jorga K; Lavé T
Clin Pharmacokinet; 2006; 45(5):511-42. PubMed ID: 16640456
[TBL] [Abstract][Full Text] [Related]
18. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
Peters SA
Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profile of bitopertin, a selective GlyT
Frouni I; Bédard D; Bourgeois-Cayer É; Hamadjida A; Gaudette F; Beaudry F; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1053-1060. PubMed ID: 36633618
[TBL] [Abstract][Full Text] [Related]
20. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.
Polasek TM; Tucker GT; Sorich MJ; Wiese MD; Mohan T; Rostami-Hodjegan A; Korprasertthaworn P; Perera V; Rowland A
Br J Clin Pharmacol; 2018 Mar; 84(3):462-476. PubMed ID: 29194718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
